期刊
MOLECULES
卷 26, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/molecules26164822
关键词
glucagon-like peptide-1; dipeptidyl peptidase-4; haemoglobin A1c; systolic blood pressure; atherosclerosis; mononuclear cells; vascular smooth muscle cells; mitochondria; endothelial cells
GLP-1 RAs are considered the standard of care for type 2 diabetes in many countries due to their strong anti-hyperglycemic effects and favorable safety profile. Recent CV outcome trials have shown that these molecules reduce major adverse cardiovascular events and improve surrogate markers associated with CV risk, prompting further research into their cardiovascular protective qualities.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are considered the standard of care for type 2 diabetes in many countries worldwide. These molecules have profound anti-hyperglycaemic actions with a favourable safety profile. They are now being considered for their robust cardiovascular (CV) protective qualities in diabetic patients. Most recent CV outcome trials have reported that GLP-1 RAs reduce major adverse cardiovascular events (MACE). Furthermore, the GLP-1 RAs seem to target the atherosclerotic CV disease processes preferentially. GLP-1 RAs also improve a wide range of routinely measured surrogate markers associated with CV risk. However, mediation analysis suggests these modest improvements may contribute indirectly to the overall anti-atherogenic profile of the molecules but fall short in accounting for the significant reduction in MACE. This review explores the body of literature to understand the possible mechanisms that contribute to the CV protective profile of GLP-1 RAs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据